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Mallory bodies (MBs) are intracytoplasmic bodies seen in hepatocytes of alcoholic liver 
disease, primary biliary cirrhosis and hepatocellular carcinoma.  However, the mecha-
nism of MB formation has not been fully understood.  Proteins could be modiﬁed to ad-
vanced glycation end products (AGEs) after long-term incubation with reducing sugar. 
AGEs are known to accumulate in several tissues in aging and age-enhanced disorders. 
To study the possible glycation process in the formation of MBs, hepatocytes of 80 human 
liver tissues with MBs were subjected to immunohistochemical analyses with ﬁve AGEs, 
two markers for oxidative stress proteins (OSPs) and four stress-response proteins (SRPs). 
MBs in hepatocytes of primary biliary cirrhosis and alcoholic liver disease were strongly 
positive for -(carboxymethyl)lysine (CML) and weakly positive for pyrraline.  MBs in 
hepatocellular carcinomas were negative for both CML and pyrraline.  No significant 
immunoreactivity was detected in MBs for other AGEs, such as -(carboxyethyl)lysine, 
pentosidine, and 3DG-imidazolone, or for OSPs and SRPs.  Stainings for cytokeratin, 
a major protein component of MBs, and CML were co-localized.  Furthermore, immu-
noblot analysis suggested that cytokeratin of MBs was modiﬁed to AGE, since a single 
protein band detected by a monoclonal anti-CML had a molecular weight identical to cy-
tokeratin.  The absence of the CML signal in MBs of hepatocellular carcinoma cells could 
be explained by scarce content of cytokeratin in carcinoma MBs. 
Key words: advanced glycation end product; cytokeratin; immunohistochemistry; Mallory 
body; -(carboxymethyl)lysine
Abbreviations: ABC, avidin-biotin-immunoperoxidase complex; AEC, 3-amino-9-ethylcarbazole; AGE, advanced gly-
cation end product; BSA, bovine serum albumin; CEL, -(carboxyethyl)lysine; CML, -(carboxymethyl)lysine; DAB, 
3,3'-diaminobenzidine tetrahydrochloride; HCC, hepatocellular carcinoma; H&E staining, hematoxylin and eosin stain-
ing-; HNE, 4-hydroxy-2-nonenal; MB, Mallory body; PAS, periodic acid Schiff; PBC, primary biliary cirrhosis; SDS, 
sodium dodecyl sulfate; SRP, stress-response protein
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Mallory first described cytoplasmic hyaline de-
generation in hepatocytes of alcoholic liver cir-
rhosis (Mallory, 1911).  This cytoplasmic hyaline 
inclusion has been called Mallory body (MB). 
MB had been thought as speciﬁc to alcoholic liver 
disease (Edmondson, 1986).  However, they are 
also associated with a number of non-alcoholic 
hepatobiliary diseases, such as Indian childhood 
cirrhosis, primary biliary cirrhosis (PBC), Wil-
son’s disease, hepatocellular carcinoma (HCC) 
and adenomatous hyperplasia (Jensen and Gluud, 
1994a; Terada et al., 1989).  Although several 
different theories have been proposed for the 
formation of MBs (Jensen and Gluud, 1994b), 
the mechanism of MB formation as well as their 
developmental and pathological significance has 
remained unknown. 
 Ultrastructurally MBs consist of aggregates 
of ﬁlaments (Yokoo et al., 1972), and aberrant in-
termediate ﬁlaments of cytokeratin polypeptides 
(Katsuma et al., 1987).  Recently, hyperphos-
phorylation of cytokeratin 8 and 18 (Stumptner 
et al., 2000) or ubiquitination of cytokeratin pro-
teins was revealed in MB formation (Yuan et al., 
1996).  MBs were also known to be positive for 
B-crystallin immunohistochemically (Lowe et al., 
1992).  Namely, MBs contain protein components 
such as cytokeratin, ubiquitin or B-crystallin. 
Furthermore, the other chemical analyses dem-
onstrated that MBs possess carbohydrates (Lyon 
and Christoffersen, 1971) and reducing sugar 
(Luisada-Opper et al., 1977) in addition to cyto-
keratin as the major protein component.
 Long-term incubation of proteins with glucose 
leads, through the formation of early products 
such as Schiff base and Amadori rearrangement 
products, to the formation of advanced glyca-
tion end products (AGEs).  Since monoclonal or 
polyclonal antibodies against these AGEs have 
been newly produced, immunological studies us-
ing anti-AGE antibodies have demonstrated ac-
cumulation of AGE-modiﬁed proteins in several 
human tissues in association with aging (Araki 
et al., 1992; Kimura et al., 1996) and several dis-
orders such as diabetic complications (Makino et 
al., 1995), atherosclerosis (Kume et al., 1995) and 
Alzheimer’s disease (Smith et al., 1994).  AGE-
modiﬁcation is known to occur in many proteins, 
especially long-lived proteins, which makes them 
insoluble, thus enhancing the deposition of modi-
ﬁed proteins inside the cells or in the extracellular 
space (Makino et al., 1995; Giardino et al., 1996). 
Finally, AGE-modiﬁed proteins that are accumu-
lated in the tissues exhibit direct toxic effects on 
cells biologically (Vlassara et al., 1994).
 AGE-structures reported so far include ﬂuo-
rescent and cross-linking structures such as pen-
tosidine (Sell and Monnier, 1990) and crossline 
(Nakamura et al., 1992), and nonﬂuorescent and 
non-cross-linked structures such as imidazolone 
(Niwa et al., 1997), -(carboxymethyl)lysine 
(CML) (Ahmed et al., 1986) and pyrraline (Hayase 
et al., 1989).  The purpose of the present study 
was to investigate whether AGE-modification 
could play a role in MB formation.  To do this 
end, human liver tissues with MBs were examined 
immunohistochemically using antibodies against 
CML, -(carboxyethyl)lysine (CEL), pyrraline, 
pentosidine and 3DG-imidazolone.  Our results 
revealed that chemical modiﬁcation of cytokera-
tin by CML, a major antigenic AGE-structure, is 
involved in MB formation in hepatocytes in alco-
holic liver disease and primary biliary cirrhosis 





Eight hundred liver tissues from autopsy, biopsy 
and surgical ﬁles kept in our Department and Di-
vision were surveyed from 1973 to 2000, and MBs 
were found histologically in 80 cases (8 autopsy 
cases, 11 biopsy cases and 61 surgical cases).  The 
80 cases with MBs included three PBC cases (fe-
males, aged 37 to 68 years), 17 cases of alcoholic 
liver disease (15 males and 2 females, aged 33 to 
66 years) and 60 cases of HCC (52 males and 8 
females, aged 29 to 80 years).  Surgical and au-
topsy specimens of normal liver tissues and other 
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Table 1. Sources of primary antibodies and dilutions
       Antibody   Clonality Clone Dilution Source (reference)
Anti-MB-component protein antibody
    Cytokeratin, broad Monoclonal  Ready-to-use Nichirei (Tokyo, Japan)
    B-crystallin Polyclonal  1:250 J. E. Goldman (Iwaki et al., 1989)
    Ubiquitin  Polyclonal  1:1000 S. H. Yen (Lee et al., 1989)
 Anti-AGE antibody
 CML Monoclonal 6D12 0.5 μg/mL S. Horiuchi (Ikeda et al., 1996)
  Monoclonal CMS10 0.5 μg/mL Kumamoto Immunochem. Lab. (Kumamoto, Japan)
 Pyrraline Polyclonal  1.0 μg/mL S. Horiuchi (Hayase et al., 1989)
 Pentosidine Polyclonal  1.0 μg/mL S. Horiuchi (Miyata et al., 1996)
 CEL Monoclonal KNH-30 0.6 μg/mL Kumamoto Immunochem. Lab. (Kumamoto, Japan)
 3DG-imidazolone Monoclonal JNH-27 0.5 μg/mL Kumamoto Immunochem. Lab. (Kumamoto, Japan)
Anti-OSP antibody
 Acrolein Monoclonal  0.5 μg/mL NOF (Tokyo, Japan)
 4-HNE Monoclonal  0.5 μg/mL JICA (Fukuroi, Japan)
 Anti-SRP antibody
 SRP27 Monoclonal  Ready-to-use BioGenex (San Rmon, CA)
 SRP32 Monoclonal  1:200 Santa Cruz (Santa Cruz, CA)
 SRP72 Monoclonal  1:500 Amersham (Buckinghamshire, United Kingdom)
 SRP90 Monoclonal  1:5000 Afﬁnity BioReagent (Neshanic Station, NJ)
AGE, advance glycation end product; CEL, -(carboxyethyl)lysine; CML, -(carboxymethyl)lysine; 4-HNE, 4-hydroxy-2-
nonenal; MB, Mallory body; OSP, oxidative stress protein; SRP, stress response protein.
organ tissues from 10 individuals (7 males and 3 
females; aged 19 to 68 years) were also examined 
as controls.  The protocols were approved by the 
Ethics Committee in Tottori University Faculty of 
Medicine (No. 761).
Histology and immunohistochemistry
After ﬁxation in 10% buffered formalin, the spec-
imens were embedded in parafﬁn, cut into 4-μm-
thick sections and examined by light microscopy. 
Liver sections were stained by the following 
routine methods: hematoxylin and eosin (H&E), 
periodic acid-Schiff (PAS), digestive PAS, silver 
and azan stainings.  The distribution patterns of 
MBs were classiﬁed according to the method of 
Nakanuma and Ohta (1986).  HCCs were graded 
into grades I, II and III according to the histologi-
cal grading system of Edmondson and Steiner 
(1954).  Serial sections were used for immuno-
histochemical analysis.  The sources of primary 
antibodies and their dilutions used are listed in 
Table 1.  Sections were deparafﬁnized and endog-
enous peroxidase activity was quenched for 30 
min with 0.3% H2O2.  Sections were then washed 
in phosphate-buffered saline (PBS), pH 7.4.  Nor-
mal sera isologous with each secondary antibody 
were used as blocking reagents.  Sections were 
incubated with one of the primary antibodies 
or PBS for 18 h at 4°C.  As positive controls for 
CML-immunostaining, atherosclerotic lesions in 
the wall of aortae from control individuals were 
used, biopsy specimens of diabetic kidney for 
pyrraline or pentosidine staining and atheroscle-
rotic tissues also served as positive controls for 
acrolein and HNE stainings.  Some sections were 
incubated with anti-CML antibody that had been 
preabsorbed with 1 mg/mL of CML-modiﬁed bo-
vine serum albumin (BSA).  With respect to the 
preabsorption test, some sections were incubated 
with anti-CML, anti-pyrraline, or anti-pentosidine 
antibody that had been preabsorbed with excess 
CML-, pyrraline- or pentosidine-modified BSA, 
respectively.  Bound antibodies were visualized 
by the avidin-biotin-immunoperoxidase complex 
(ABC) method using the appropriate Vectastain 
86
M. Kato et al.
Table 2. Clinicopathological ﬁndings of 20 cas-
es of PBC and ALD with MBs
 Case  Age Sex Clinical Histopathology
 number   diagnosis 
 1 37 F PBC LC/biliary
 2 61 F PBC LC/biliary 
 3 68 F PBC LC/biliary 
 4 56 M ALD Fatty liver
 5 44 M ALD AH
 6 54 M ALD AH
 7 47 M ALD AH
 8 61 M ALD AH
 9 37 M ALD Fibrosis
 10 47 M ALD Fibrosis
 11 49 F ALD Fibrosis
 12 57 M ALD Fibrosis
 13 65 M ALD Fibrosis
 14 66 M ALD Fibrosis
 15 37 F ALD LC/septal
 16 56 M ALD LC/septal
 17 59 M ALD LC/septal
 18 70 M ALD LC/septal
 19 33 M ALD LC/septal
 20 61 M ALD LC/septal
AH, alcoholic hepatitis; ALD, alcoholic liver disease; F, fe-
male; LC/biliary, liver cirrhosis of biliary type (by Havana 
classiﬁcation) (Sherlock, 1956); LC/septal, liver cirrhosis of 
septal type; M, male; MB, Mallory body; PBC, primary bili-
ary cirrhosis.
ABC kit (Vector Laboratories, Burlingame, CA) 
and 3,3'-diaminobenzidine tetrahydrochloride 
(DAB) (Dako, Glostrup, Denmark) as the final 
chromogen.  For labeling multiple antigens in 
the same tissue section, normal and abnormal 
structures in H&E-stained sections were identi-
ﬁed, mapped and photomicrographed.  The H&E 
sections were then decolorized in 70% ethanol 
containing 1% HCl, after which the sections were 
rehydrated, quenched for 30 min with 0.3% H2O2, 
rinsed in PBS and incubated with the ﬁrst prima-
ry antibody for 18 h at 4°C.  Bound antibody was 
visualized by the ABC method using 3-amino-9-
ethylcarbazole (AEC; Vector Laboratories) as the 
chromogen, yielding a red product.  After pho-
tographing the immunoreactive structures, AEC 
sections were decolorized using 100% ethanol, 
rinsed twice in PBS and incubated for 60 min at 
room temperature with glycine-HCl buffer (pH 
2.2) to elute the immunoreactive products.  The 
completeness of the elution process was veri-
fied by obtaining a negative reaction after reap-
plication of the appropriate ABC kit including a 
secondary antibody and AEC on the eluted sec-
tions.  The sections were subsequently incubated 
with the second primary antibody for 18 h at 4°
C, and immunoreactivity was visualized by the 
ABC method using DAB as the chromogen.  The 
proportion of positively-immunostained MBs was 
classiﬁed into ﬁve different categories; category – 
means negative staining, category +/– a few MBs 
were stained weakly, category + less than 10%, 
category ++ 10–50% and category +++ more than 
50%.
Immunoblot analysis
This analysis was carried out on one fresh liver 
sample of a patient with PBC (Patient 2, a 61-year-
old female) and on a liver tissue of age-matched 
normal individual (a 68-year-old female).  In 
brief, specimens were homogenized in Laemmli 
sample buffer (Bio-Rad, Hercules, CA) containing 
2% sodium dodecyl sulfate (SDS), 25% glycerol, 
10% 2-mercaptoethanol, 0.01% bromophenol blue 
and 62.5 mM Tris-HCl, pH 6.8.  The sample was 
heated at 100°C for 5 min.  Soluble protein ex-
tracts from the samples were separated on a SDS-
polyacrylamide gel (10%–20% gradient, Bio-Rad) 
and transferred by electroblotting onto Immobilon 
PVDF (Millipore, Bedford, MA).  After blocking 
with 5% skimmed milk for 30 min at room tem-
perature, the blots were incubated with anti-CML 
antibody (6D12) overnight at 4°C and visualized 
with the Vectastain ABC kit and DAB.  Appro-
priate molecular weight markers (Bio-Rad) were 
included in each run.  
Results
Histology and immunohistochemistry
Three cases clinically diagnosed as PBC showed 
histopathologically liver cirrhosis, biliary (Table 2). 
The histopathological ﬁndings of 17 cases clini-
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Fig. 1.  Hematoxylin and eosin staining of liver tissue of 
Patient 2 with primary biliary cirrhosis (PBC) (A) and 
the patient with hepatocellular carcinoma (B), showing 
Mallory bodies (MBs) (arrows).  Bar = 100 μm. 
cally diagnosed as alcoholic liver disease, showed 
fatty liver (1 case), alcoholic hepatitis (4 cases), 
liver fibrosis (6 cases) and liver cirrhosis (sep-
tal type, 6 cases) by routine stainings (Table 2). 
Sixty cases of HCCs were classiﬁed as the grade 
I (15 cases), the grade II (41 cases) and the grade 
III (4 cases).  MBs were found predominantly in 
peripheral areas of regenerative nodules of liver 
cirrhosis in PBC (Fig. 1A) and alcoholic liver 
disease, and also in periportal areas of ﬁbrotic al-
coholic liver disease.  MBs were scattered in fatty 
liver and in alcoholic hepatitis.  MBs in HCCs 
were found in the cancer tissues (Fig. 1B).  The 
ratio of MB-bearing hepatocytes to total hepato-
cytes varied from a few to ~10 percent in liver ﬁ-
brosis, liver cirrhosis and HCCs.  The distribution 
patterns of MBs of PBC were classiﬁed as diffuse 
type (2 cases) and sparse type (1 case).  The pat-
terns of MBs of alcoholic liver disease were clas-
siﬁed as diffuse type (2 cases) and as sparse type 
(15 cases).  The patterns of MBs of HCCs were as 
clustering type (21 cases), diffuse type (26 cases) 
and sparse type (13 cases) (Table 3).
 The shape of MBs in PBC and alcoholic 
liver disease showed granular (Fig. 2A), staghorn, 
or circlar pattern (Fig. 2D).  In contrast, the shape 
of MBs in HCCs was irregular (Fig. 1B).  MBs 
of alcoholic liver disease, PBC and HCCs were 
Table 3.  Histopathological and immunohistochemical ﬁndings of 80 cases of PBC, ALD and HCC 
with MBs
 Distribution Number CML CML Pyrraline Pentosidine CEL Cyto-
 pattern  of cases (6D12) (CMS10)    keratin
PBC Clustering 0
 Diffuse 2 +~+++ +~+++ +/–~– – – ++
 Sparse 1 + + – – – ++
Alcoholic liver disease Clustering 0
 Diffuse 2 +~++ +~++ +/– – – ++
 Sparse 15 + + +/–~– – – ++
Hepatocellular carcinoma Clustering 21
 Diffuse 26 – – – – – +/–
 Sparse 13 – – – – – +/–
CEL, -(carboxyethyl)lysine; CML, -(carboxymethyl)lysine; MB, Mallory body; PBC, primary biliary cirrhosis.
Distribution patterns of MBs were divided according to Nakanuma and Ohta (1986). 
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weakly positive for PAS histochemically (data 
not shown).  The PAS-positivity was confirmed 
by the digestive PAS staining.  MBs in PBC and 
alcoholic liver disease were conﬁrmed immuno-
histochemically by positive staining to ubiquitin 
and B-crystallin addition to H&E staining.  The 
reaction products within MBs in PBC by the anti-
CML antibody exhibited a granular pattern (Fig. 
2B) or a circular pattern (Fig. 2E).  MBs and MB-
bearing hepatic cytoplasm were also stained with 
the anti-cytokeratin antibody (Figs. 2C and F). 
The positive reaction products for both CML and 
Fig. 2.  Light microscopic characteristics of the Mallory bodies (MBs) of Patient 
2 with primary biliary cirrhosis.
A: An MB in hematoxylin and eosin (H&E) staining (arrows).  Bar = 10 μm 
(A–F: same magniﬁcation).
B: The same section as A immunostained for -(carboxymethyl)lysine (CML) 
using 3-amino-9-ethylcarbazole (AEC) as chromogen (arrowheads). 
C: The section used in B was decolorized and restained for cytokeratin using 
3,3'-diaminobenzidine tetrahydrochloride (DAB) as chromogen (arrows). 
D: An MB in H&E staining (arrows). 
E: The section used in D was decolorized and immunostained for CML using 
AEC as chromogen.  A doughnut-shaped MB is stained in red (arrowheads).
F: The section used in E was decolorized and restained for cytokeratin using 
DAB as chromogen showing the MB (arrows).
Fig. 3.  Liver sections of the pa-
tient with hepatocellular carcino-
ma.  Immunostaining for ubiquitin 
(A) and CML (with monoclonal 
antibody 6D12) (B). Bar = 100 μm 
(A and B: same magniﬁcation).
cytokeratin were co-localized on the same MBs 
(Figs. 2B and C; and Figs. 2E and F, respectively). 
 MBs derived from three cases of PBC and 
17 cases of alcoholic liver disease were posi-
tively stained to CML (both clone of 6D12 and 
CMS-10) (Table 3).  MBs in one case of PBC and 
nine cases of alcoholic liver disease were weakly 
stained with anti-pyrraline antibody.  MBs of all 
cases of both PBC and alcoholic liver disease 
showed positive for cytokeratin.  MBs were not 
stained by anti-pentosidine antibody, anti-CEL 
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MBs were not stained with antibodies against 
oxidative stress proteins (OSPs) such as acrolein 
and HNE nor against stress response proteins 
(SRPs) (27 kDa, 32 kDa, 72 kDa or 90 kDa) (data 
not shown).  MBs in HCCs were also identified 
by positive staining to anti-ubiquitin antibody 
(Fig. 3A).  MBs in all cases of HCCs were weakly 
stained by anti-cytokeratin antibody.  By contrast, 
MBs in HCCs were not stained to CML (Fig. 3B), 
pyrraline, pentosidine, CEL, 3DG-imidazolone, 
two types of OSPs (acrolein and HNE) nor four 
types of SRPs (srp27, 32, 72 and 90).  There were 
no significant differences in AGE-expressions 
among the histologically different specimens in 
HCCs. 
 The proportion of positively-immunostained 
MBs varied from one sample to another, rang-
ing from less than 10% to more than 50% of total 
MBs (Table 3).  Immunohistochemical stain-
ings of CML of PBC and alcoholic liver disease 
showed that 1 out of 20 cases was of category 
+++; 4 out of 20 cases were of category ++, and 
15 cases out of 20 cases were of category +.  Im-
munohistochemical stainings of pyrraline of PBC 
and alcoholic liver disease showed that one case 
of PBC was of category +/– and nine of 17 cases 
of alcoholic liver disease were of category +/–. 
MBs with diffuse distribution pattern were posi-
tive for CML or pyrraline more than MBs with 
sparse type.  All cases of PBC and alcoholic liver 
disease were of category ++ about cytokeratin. 
All cases of HCC were of category +/– about cy-
tokeratin. 
 Hepatocytes from 10 control individuals 
were not stained by five anti-AGE antibodies 
against either of CML, pyrraline, pentosidine, 
CEL or 3DG-imidazolone.  Similarly, normal he-
patocytes showed no immunoreactivities to OSPs, 
SRPs, B-crystallin nor ubiquitin.  No staining 
was detected when sections were incubated with 
PBS.  The specificity and high affinity of these 
antibodies were conﬁrmed by control tissues.  As 
expected (Makino et al., 1995; Kume et al., 1995; 
Horie et al., 1997), CML-immunoreactivities were 






Fig. 4. Western blot analysis 
using monoclonal CML (with 
monoclonal antibody 6D12) in 
liver tissues.  
Lane 1: normal control liver.
Lane 2: primary biliary cirrho-
sis liver (Patient 2). 
lesions, and immunoreactivities for pyrraline, 
pentosidine, CEL and 3DG-imidazolone were also 
noted in the thickening intimae of arteries.  As re-
ported earlier (Uchida et al., 1995), macrophage-
derived foam cells in the atheromatous lesions 
were positive for HNE.  Anti-CML antibody pre-
treated with an excess amount of CML-modiﬁed 
BSA did not stain smooth muscle cells in the ath-
erosclerotic lesions.  Similarly, anti-pyrraline, or 
anti-pentosidine antibody pretreated with an ex-
cess amount of pyrraline- or pentosidine-modiﬁed 
BSA did not stain the thickening intimae of arter-
ies. 
Immunoblot analysis
The results of immunoblot analyses are shown in 
Fig. 4.  When the liver-tissue homogenate of PBC 
(Patient 2, a 61-year-old female), whose hepato-
cytes were demonstrated to contain CML-positive 
MBs immunochemically, was subjected to immu-
noblotting with anti-CML antibody, a single band 
with a molecular weight indistinguishable from 
that of cytokeratin was detected (Fig. 4).  Immu-
noblotting of the fresh autopsy liver specimen of 
a normal individual (a 68-year-old female) did not 
show any speciﬁc band (Fig. 4). 
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Discussion
Although the frequency and the distribution of 
MBs that were detected by H&E staining were 
various among 80 cases examined, all of the MBs 
were positive for ubiquitin, B-crystallin and cy-
tokeratin immunohistochemically.  MBs in HCCs 
were weakly positive for cytokeratin, but MBs 
in PBC and alcoholic liver disease were strongly 
positive for cytokeratin.  The present immuno-
histochemical results coincide with the previous 
reports which demonstrated that MBs consisted 
of aggregates of cytokeratin ﬁlaments (Yokoo et 
al., 1972) or that cytokeratin protein of MBs was 
ubiquitinated (Yuan et al., 1996).  In the pres-
ent study, the facts that MBs contain cytokeratin, 
ubiquitin and B-crystallin as protein components 
were conﬁrmed immunohistochemically.
 The novel finding of the present study is 
that MBs in PBC and alcoholic liver disease were 
positive for CML and pyrraline in contrast to 
those of HCCs.  In cases of PBC and alcoholic 
liver disease, immunohistochemical results of 
the same paraffin sections using anti-CML and 
anti-cytokeratin antibodies, revealed that both 
CML and cytokeratin were co-localized on the 
same MBs.  These results suggest that MBs in 
PBC and alcoholic liver disease have epitopes of 
CML addition to cytokeratin.  No CML-positive 
reactivities except MBs were found in the liver 
sections of PBC, alcoholic liver disease, HCCs 
and normal controls.  Furthermore, immunoblot 
analysis with anti-CML antibody supported the 
immunohistochemical ﬁndings.  Single band with 
a molecular weight about 55 kDa was detected 
in the liver-tissue homogenate of PBC.  This re-
sult demonstrated that liver tissue-homogenate 
of PBC contain CML-combined protein with 
molecular weight about 55 kDa.  Considering the 
fact that the molecular weight of ubiquitin, one of 
protein components of MBs is about 8 kDa (Lee 
et al., 1989; Lowe and Mayer, 1990) and that of 
B-crystallin is also 22 kDa (Iwaki et al., 1989), it 
was suggested that CML-combined protein might 
be cytokeratin.
 Glycation is one of biochemical reactions and 
it occurs when proteins were incubated with re-
ducing sugars.  Finally, CML, CEL or pyrraline-
combined proteins through several steps by glyca-
tion form AGEs.  Although oxidation is necessary 
for the formation of AGEs in vitro (Nagai et al., 
1997), the intention level of oxidation, the nature 
of oxidative processes, and the period of oxidative 
stresses are of different in vivo.  At the cellular 
level, living cells can induce a diverse group of 
SRPs in response to different types of biological 
stresses, including oxidative damage (Morimoto 
et al., 1990).  Since OSPs and SRPs in MBs were 
not detected in the present immunohistochemical 
studies, the amounts of these compounds in MBs 
might be, if any, negligible, suggesting that the 
oxidative stress that generates these marker com-
pounds does not contribute to the process of MB 
formation in vivo. 
 Modification by glycation occurs in many 
proteins in relation to the pathogenesis of dis-
eases such as atherosclerosis (Kume et al., 1995), 
diabetic complications (Makino et al., 1995), 
Alzheimers’ disease (Smith et al., 1994).  Fur-
thermore, AGEs are common to be long-lived, 
insoluble molecules, readily deposited in cells 
that have a direct cytotoxic effect (Vlassara et al., 
1994).  Although several hypotheses of MBs have 
been discussed (Jensen and Gluud, 1994a, 1994b) 
the results of the present study clariﬁed that AGE-
modiﬁcation of cytokeratin, a major protein com-
ponent of MBs, plays an important role in the for-
mation of MBs in hepatocytes in the PBC and the 
alcoholic liver disease.  Taken together with ab-
normal cytokeratin aggregation toxicity, it is con-
ceivable that the AGE modiﬁcation of cytokeratin 
in MBs could amplify the aggregation of cyto-
keratin and that the formation of the AGEs could 
result in greater toxicity in hepatocytes-bearing 
MBs in patients with the PBC and alcoholic liver 
disease.  Considering the facts that MBs of HCCs 
contain less amount of cytokeratin protein, HCC 
cells form MBs for a short disease duration of tu-
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morigenesis or have abnormal biological metabo-
lism, AGE-modiﬁcation do not contribute to the 
formation of the MBs in HCC cells.  To elucidate 
the differences between AGE-expressions of alco-
holic liver disease or PBC and AGE-expressions 
of HCCs, a further complete understanding of the 
molecular mechanisms of MB formation in hepa-
tocytes will be necessary.  Our results suggest that 
the formation of AGEs might be cytotoxic to MB-
containing hepatocytes in PBC and alcoholic liver 
disease in contrast to HCCs.
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